A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Trial details

Who runs it

Novartis Pharmaceuticals

Trial code

NCT06840392EU 2024-513266-19-00

Record updated

15 October 2026

Original description

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).Read full original descriptionShow less

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Inclusion: Male and female participants ≥ 12 years of age at the time of signing of the informed consent; Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the Baseline visit; Participants with moderate to severe HS defined as:; A total of at least 5 AN count (abscesses and/or inflammatory nodules) AND; Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae).

Exclusion: Previous exposure to remibrutinib or other BTK inhibitors; Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer; History of live attenuated vaccine administration within 6 weeks prior to randomization or requirement to receive these vaccinations at any time while on study treatment; Major surgery within 8 weeks prior to screening or planned surgery for the duration of the study; Other protocol-defined inclusion/exclusion criteria may apply; Any active skin disease or conditions that may interfere with the assessment of HS; Significant bleeding risk or coagulation disorders; History of gastrointestinal bleeding; History or current hepatic disease; Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the Investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant; History of hypersensitivity to any of the study drug constituents; Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the trial as per investigator's assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility; Requirement for anti-platelet (except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d) or anti-coagulant medication; Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline.

ClinicalTrials.gov NCT06840392 · EU CTIS 2024-513266-19-00